Structural characteristics of small-molecule antifolate compounds

Carl H. Schwalbe*, Vivian Cody

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Because of the importance of dihydrofolate reductase (DHFR) inhibitors in the treatment of infections and cancer, a wealth of structural information has been collected. Small-molecule crystallography has been carried out on the drugs alone or in salts, and macromolecular crystallography on the drugs bound to DHFR from a number of different species. This review provides an analysis of the small-molecule data. The natural substrates of DHFR contain the pterin (2-amino-4-oxopteridine) ring system, and the ring geometry is compared as this system is changed to the 2,4-diamino analogue found in inhibitors and/or simplified to a single ring and/or subjected to steric hindrance. Clinically useful antifolates have separate ring systems linked by three rotatable bonds as in methotrexate, or two as in trimethoprim, or one as in pyrimethamine. In the latter two cases enough structures are available to provide a clear picture of the preferred disposition(s) of rings around the linkages. Because a very important interaction between inhibitors and DHFR is a pair of hydrogen bonds from the protonated 2,4-diaminopyrimidine moiety of the inhibitor to a carboxylate anion from DHFR, its geometry in small-molecule salts with oxyanions is expressed in terms of deformations from a fiducial arrangement and also subjected to cluster analysis. Finally, the supramolecular interactions in the small-molecule structures are built up from two modules describing the interactions at the 1- and 2-positions and at the 3- and 4-positions of the 2,4-diamino- or 2-amino-4-oxopyrimidine moieties. Reassuringly for drug design, the following review will show that the molecular conformations and supramolecular interactions of inhibitors bound to DHFR match reasonably well-populated subsets found in the small-molecule context here.

Original languageEnglish
Pages (from-to)267-300
Number of pages34
JournalCrystallography Reviews
Volume12
Issue number4
DOIs
Publication statusPublished - 1 Oct 2006

Fingerprint

Folic Acid Antagonists
Tetrahydrofolate Dehydrogenase
inhibitors
Crystallography
Molecules
rings
drugs
molecules
Pair Bond
Salts
crystallography
Pterins
Molecular Conformation
Pyrimethamine
Trimethoprim
interactions
Pharmaceutical Preparations
Drug Design
salts
cluster analysis

Keywords

  • Antifolate compounds
  • DHFR
  • Small-molecule crystallography

Cite this

Schwalbe, Carl H. ; Cody, Vivian. / Structural characteristics of small-molecule antifolate compounds. In: Crystallography Reviews. 2006 ; Vol. 12, No. 4. pp. 267-300.
@article{b2277a5d2a5942469579355817a72ade,
title = "Structural characteristics of small-molecule antifolate compounds",
abstract = "Because of the importance of dihydrofolate reductase (DHFR) inhibitors in the treatment of infections and cancer, a wealth of structural information has been collected. Small-molecule crystallography has been carried out on the drugs alone or in salts, and macromolecular crystallography on the drugs bound to DHFR from a number of different species. This review provides an analysis of the small-molecule data. The natural substrates of DHFR contain the pterin (2-amino-4-oxopteridine) ring system, and the ring geometry is compared as this system is changed to the 2,4-diamino analogue found in inhibitors and/or simplified to a single ring and/or subjected to steric hindrance. Clinically useful antifolates have separate ring systems linked by three rotatable bonds as in methotrexate, or two as in trimethoprim, or one as in pyrimethamine. In the latter two cases enough structures are available to provide a clear picture of the preferred disposition(s) of rings around the linkages. Because a very important interaction between inhibitors and DHFR is a pair of hydrogen bonds from the protonated 2,4-diaminopyrimidine moiety of the inhibitor to a carboxylate anion from DHFR, its geometry in small-molecule salts with oxyanions is expressed in terms of deformations from a fiducial arrangement and also subjected to cluster analysis. Finally, the supramolecular interactions in the small-molecule structures are built up from two modules describing the interactions at the 1- and 2-positions and at the 3- and 4-positions of the 2,4-diamino- or 2-amino-4-oxopyrimidine moieties. Reassuringly for drug design, the following review will show that the molecular conformations and supramolecular interactions of inhibitors bound to DHFR match reasonably well-populated subsets found in the small-molecule context here.",
keywords = "Antifolate compounds, DHFR, Small-molecule crystallography",
author = "Schwalbe, {Carl H.} and Vivian Cody",
year = "2006",
month = "10",
day = "1",
doi = "10.1080/08893110701337800",
language = "English",
volume = "12",
pages = "267--300",
journal = "Crystallography Reviews",
issn = "0889-311X",
publisher = "Taylor & Francis",
number = "4",

}

Structural characteristics of small-molecule antifolate compounds. / Schwalbe, Carl H.; Cody, Vivian.

In: Crystallography Reviews, Vol. 12, No. 4, 01.10.2006, p. 267-300.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Structural characteristics of small-molecule antifolate compounds

AU - Schwalbe, Carl H.

AU - Cody, Vivian

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Because of the importance of dihydrofolate reductase (DHFR) inhibitors in the treatment of infections and cancer, a wealth of structural information has been collected. Small-molecule crystallography has been carried out on the drugs alone or in salts, and macromolecular crystallography on the drugs bound to DHFR from a number of different species. This review provides an analysis of the small-molecule data. The natural substrates of DHFR contain the pterin (2-amino-4-oxopteridine) ring system, and the ring geometry is compared as this system is changed to the 2,4-diamino analogue found in inhibitors and/or simplified to a single ring and/or subjected to steric hindrance. Clinically useful antifolates have separate ring systems linked by three rotatable bonds as in methotrexate, or two as in trimethoprim, or one as in pyrimethamine. In the latter two cases enough structures are available to provide a clear picture of the preferred disposition(s) of rings around the linkages. Because a very important interaction between inhibitors and DHFR is a pair of hydrogen bonds from the protonated 2,4-diaminopyrimidine moiety of the inhibitor to a carboxylate anion from DHFR, its geometry in small-molecule salts with oxyanions is expressed in terms of deformations from a fiducial arrangement and also subjected to cluster analysis. Finally, the supramolecular interactions in the small-molecule structures are built up from two modules describing the interactions at the 1- and 2-positions and at the 3- and 4-positions of the 2,4-diamino- or 2-amino-4-oxopyrimidine moieties. Reassuringly for drug design, the following review will show that the molecular conformations and supramolecular interactions of inhibitors bound to DHFR match reasonably well-populated subsets found in the small-molecule context here.

AB - Because of the importance of dihydrofolate reductase (DHFR) inhibitors in the treatment of infections and cancer, a wealth of structural information has been collected. Small-molecule crystallography has been carried out on the drugs alone or in salts, and macromolecular crystallography on the drugs bound to DHFR from a number of different species. This review provides an analysis of the small-molecule data. The natural substrates of DHFR contain the pterin (2-amino-4-oxopteridine) ring system, and the ring geometry is compared as this system is changed to the 2,4-diamino analogue found in inhibitors and/or simplified to a single ring and/or subjected to steric hindrance. Clinically useful antifolates have separate ring systems linked by three rotatable bonds as in methotrexate, or two as in trimethoprim, or one as in pyrimethamine. In the latter two cases enough structures are available to provide a clear picture of the preferred disposition(s) of rings around the linkages. Because a very important interaction between inhibitors and DHFR is a pair of hydrogen bonds from the protonated 2,4-diaminopyrimidine moiety of the inhibitor to a carboxylate anion from DHFR, its geometry in small-molecule salts with oxyanions is expressed in terms of deformations from a fiducial arrangement and also subjected to cluster analysis. Finally, the supramolecular interactions in the small-molecule structures are built up from two modules describing the interactions at the 1- and 2-positions and at the 3- and 4-positions of the 2,4-diamino- or 2-amino-4-oxopyrimidine moieties. Reassuringly for drug design, the following review will show that the molecular conformations and supramolecular interactions of inhibitors bound to DHFR match reasonably well-populated subsets found in the small-molecule context here.

KW - Antifolate compounds

KW - DHFR

KW - Small-molecule crystallography

UR - http://www.scopus.com/inward/record.url?scp=35948950742&partnerID=8YFLogxK

UR - https://www.tandfonline.com/doi/abs/10.1080/08893110701337800

U2 - 10.1080/08893110701337800

DO - 10.1080/08893110701337800

M3 - Article

AN - SCOPUS:35948950742

VL - 12

SP - 267

EP - 300

JO - Crystallography Reviews

JF - Crystallography Reviews

SN - 0889-311X

IS - 4

ER -